Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

VMD vs ISRG vs HOLX vs NVCR

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
VMD
Viemed Healthcare, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$353M
5Y Perf.+10.6%
ISRG
Intuitive Surgical, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$161.07B
5Y Perf.+134.6%
HOLX
Hologic, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$16.97B
5Y Perf.+42.6%
NVCR
NovoCure Limited

Medical - Instruments & Supplies

HealthcareNASDAQ • JE
Market Cap$1.92B
5Y Perf.-75.0%

VMD vs ISRG vs HOLX vs NVCR — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
VMD logoVMD
ISRG logoISRG
HOLX logoHOLX
NVCR logoNVCR
IndustryMedical - DevicesMedical - Instruments & SuppliesMedical - Instruments & SuppliesMedical - Instruments & Supplies
Market Cap$353M$161.07B$16.97B$1.92B
Revenue (TTM)$287M$10.58B$4.13B$674M
Net Income (TTM)$15M$2.98B$544M$-173M
Gross Margin57.5%66.3%52.8%75.2%
Operating Margin8.2%30.5%17.5%-27.2%
Forward P/E19.2x43.8x17.2x
Total Debt$16M$303M$2.63B$290M
Cash & Equiv.$14M$3.37B$1.96B$103M

VMD vs ISRG vs HOLX vs NVCRLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

VMD
ISRG
HOLX
NVCR
StockMay 20May 26Return
Viemed Healthcare, … (VMD)100110.6+10.6%
Intuitive Surgical,… (ISRG)100234.6+134.6%
Hologic, Inc. (HOLX)100142.6+42.6%
NovoCure Limited (NVCR)10025.0-75.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: VMD vs ISRG vs HOLX vs NVCR

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: HOLX leads in 3 of 7 categories, making it the strongest pick for valuation and capital efficiency and capital preservation and lower volatility. Intuitive Surgical, Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. VMD also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
VMD
Viemed Healthcare, Inc.
The Growth Play

VMD is the clearest fit if your priority is growth exposure.

  • Rev growth 20.5%, EPS growth 32.1%, 3Y rev CAGR 24.9%
  • 20.5% revenue growth vs HOLX's 1.7%
Best for: growth exposure
ISRG
Intuitive Surgical, Inc.
The Long-Run Compounder

ISRG is the #2 pick in this set and the best alternative if long-term compounding is your priority.

  • 5.5% 10Y total return vs VMD's 413.5%
  • 28.2% margin vs NVCR's -25.7%
  • 14.8% ROA vs NVCR's -16.5%, ROIC 15.0% vs -16.4%
Best for: long-term compounding
HOLX
Hologic, Inc.
The Income Pick

HOLX carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.

  • beta 0.41
  • Lower volatility, beta 0.41, Low D/E 52.0%, current ratio 3.75x
  • Beta 0.41, current ratio 3.75x
  • Better valuation composite
Best for: income & stability and sleep-well-at-night
NVCR
NovoCure Limited
The Secondary Option

NVCR lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
See the full category breakdown
CategoryWinnerWhy
GrowthVMD logoVMD20.5% revenue growth vs HOLX's 1.7%
ValueHOLX logoHOLXBetter valuation composite
Quality / MarginsISRG logoISRG28.2% margin vs NVCR's -25.7%
Stability / SafetyHOLX logoHOLXBeta 0.41 vs NVCR's 2.20, lower leverage
DividendsTieNone of these 4 stocks pay a meaningful dividend
Momentum (1Y)HOLX logoHOLX+37.1% vs ISRG's -15.4%
Efficiency (ROA)ISRG logoISRG14.8% ROA vs NVCR's -16.5%, ROIC 15.0% vs -16.4%

VMD vs ISRG vs HOLX vs NVCR — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

VMDViemed Healthcare, Inc.
FY 2025
Equipment Sales
66.9%$50M
Service
33.1%$25M
ISRGIntuitive Surgical, Inc.
FY 2025
Instruments and Accessories
59.8%$6.0B
Systems
24.6%$2.5B
Services
15.6%$1.6B
HOLXHologic, Inc.
FY 2025
Diagnostics
44.6%$1.8B
Breast Health
36.2%$1.5B
Gyn Surgical
16.6%$680M
Skeletal Health
2.7%$109M
NVCRNovoCure Limited

Segment breakdown not available.

VMD vs ISRG vs HOLX vs NVCR — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLISRGLAGGINGNVCR

Income & Cash Flow (Last 12 Months)

ISRG leads this category, winning 4 of 6 comparable metrics.

ISRG is the larger business by revenue, generating $10.6B annually — 36.9x VMD's $287M. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to NVCR's -25.7%. On growth, VMD holds the edge at +27.5% YoY revenue growth, suggesting stronger near-term business momentum.

MetricVMD logoVMDViemed Healthcare…ISRG logoISRGIntuitive Surgica…HOLX logoHOLXHologic, Inc.NVCR logoNVCRNovoCure Limited
RevenueTrailing 12 months$287M$10.6B$4.1B$674M
EBITDAEarnings before interest/tax$46M$3.8B$974M-$165M
Net IncomeAfter-tax profit$15M$3.0B$544M-$173M
Free Cash FlowCash after capex$26M$2.8B$1000M-$48M
Gross MarginGross profit ÷ Revenue+57.5%+66.3%+52.8%+75.2%
Operating MarginEBIT ÷ Revenue+8.2%+30.5%+17.5%-27.2%
Net MarginNet income ÷ Revenue+5.2%+28.2%+13.2%-25.7%
FCF MarginFCF ÷ Revenue+9.0%+26.8%+24.2%-7.1%
Rev. Growth (YoY)Latest quarter vs prior year+27.5%+23.0%+2.5%+12.3%
EPS Growth (YoY)Latest quarter vs prior year0.0%+18.8%-9.2%-100.0%
ISRG leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

VMD leads this category, winning 3 of 6 comparable metrics.

At 24.9x trailing earnings, VMD trades at a 57% valuation discount to ISRG's 57.6x P/E. On an enterprise value basis, VMD's 7.2x EV/EBITDA is more attractive than ISRG's 43.6x.

MetricVMD logoVMDViemed Healthcare…ISRG logoISRGIntuitive Surgica…HOLX logoHOLXHologic, Inc.NVCR logoNVCRNovoCure Limited
Market CapShares × price$353M$161.1B$17.0B$1.9B
Enterprise ValueMkt cap + debt − cash$356M$158.0B$17.6B$2.1B
Trailing P/EPrice ÷ TTM EPS24.89x57.62x30.53x-13.80x
Forward P/EPrice ÷ next-FY EPS est.19.19x43.84x17.21x
PEG RatioP/E ÷ EPS growth rate2.65x
EV / EBITDAEnterprise value multiple7.21x43.62x17.39x
Price / SalesMarket cap ÷ Revenue1.31x16.00x4.14x2.92x
Price / BookPrice ÷ Book value/share2.62x9.17x3.43x5.51x
Price / FCFMarket cap ÷ FCF29.59x64.67x18.44x
VMD leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

ISRG leads this category, winning 6 of 9 comparable metrics.

ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-51 for NVCR. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), HOLX scores 7/9 vs VMD's 4/9, reflecting strong financial health.

MetricVMD logoVMDViemed Healthcare…ISRG logoISRGIntuitive Surgica…HOLX logoHOLXHologic, Inc.NVCR logoNVCRNovoCure Limited
ROE (TTM)Return on equity+10.5%+16.9%+11.0%-50.8%
ROA (TTM)Return on assets+7.5%+14.8%+6.1%-16.5%
ROICReturn on invested capital+11.6%+15.0%+9.4%-16.4%
ROCEReturn on capital employed+13.2%+16.5%+8.8%-28.9%
Piotroski ScoreFundamental quality 0–94675
Debt / EquityFinancial leverage0.11x0.02x0.52x0.85x
Net DebtTotal debt minus cash$2M-$3.1B$667M$187M
Cash & Equiv.Liquid assets$14M$3.4B$2.0B$103M
Total DebtShort + long-term debt$16M$303M$2.6B$290M
Interest CoverageEBIT ÷ Interest expense14.61x8.00x-96.80x
ISRG leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

ISRG leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in ISRG five years ago would be worth $15,873 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, HOLX leads with a +37.1% total return vs ISRG's -15.4%. The 3-year compound annual growth rate (CAGR) favors ISRG at 14.4% vs NVCR's -37.6% — a key indicator of consistent wealth creation.

MetricVMD logoVMDViemed Healthcare…ISRG logoISRGIntuitive Surgica…HOLX logoHOLXHologic, Inc.NVCR logoNVCRNovoCure Limited
YTD ReturnYear-to-date+27.6%-19.3%+1.9%+28.3%
1-Year ReturnPast 12 months+26.7%-15.4%+37.1%+1.1%
3-Year ReturnCumulative with dividends-14.6%+49.6%-8.5%-75.7%
5-Year ReturnCumulative with dividends-3.8%+58.7%+15.8%-91.3%
10-Year ReturnCumulative with dividends+413.5%+554.2%+124.3%+30.3%
CAGR (3Y)Annualised 3-year return-5.1%+14.4%-2.9%-37.6%
ISRG leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

HOLX leads this category, winning 2 of 2 comparable metrics.

HOLX is the less volatile stock with a 0.41 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HOLX currently trades 100.0% from its 52-week high vs ISRG's 75.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricVMD logoVMDViemed Healthcare…ISRG logoISRGIntuitive Surgica…HOLX logoHOLXHologic, Inc.NVCR logoNVCRNovoCure Limited
Beta (5Y)Sensitivity to S&P 5000.95x1.02x0.41x2.20x
52-Week HighHighest price in past year$10.18$603.88$76.04$20.06
52-Week LowLowest price in past year$5.93$427.84$52.81$9.82
% of 52W HighCurrent price vs 52-week peak+90.5%+75.1%+100.0%+83.9%
RSI (14)Momentum oscillator 0–10034.742.469.169.8
Avg Volume (50D)Average daily shares traded312K1.8M10.0M1.5M
HOLX leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: VMD as "Buy", ISRG as "Buy", HOLX as "Hold", NVCR as "Buy". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs 3.9% for HOLX (target: $79).

MetricVMD logoVMDViemed Healthcare…ISRG logoISRGIntuitive Surgica…HOLX logoHOLXHologic, Inc.NVCR logoNVCRNovoCure Limited
Analyst RatingConsensus buy/hold/sellBuyBuyHoldBuy
Price TargetConsensus 12-month target$622.60$79.00$33.50
# AnalystsCovering analysts1554215
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises2
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap+3.7%+1.4%+4.4%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

ISRG leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). VMD leads in 1 (Valuation Metrics).

Best OverallIntuitive Surgical, Inc. (ISRG)Leads 3 of 6 categories
Loading custom metrics...

VMD vs ISRG vs HOLX vs NVCR: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is VMD or ISRG or HOLX or NVCR a better buy right now?

For growth investors, Viemed Healthcare, Inc.

(VMD) is the stronger pick with 20. 5% revenue growth year-over-year, versus 1. 7% for Hologic, Inc. (HOLX). Viemed Healthcare, Inc. (VMD) offers the better valuation at 24. 9x trailing P/E (19. 2x forward), making it the more compelling value choice. Analysts rate Viemed Healthcare, Inc. (VMD) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — VMD or ISRG or HOLX or NVCR?

On trailing P/E, Viemed Healthcare, Inc.

(VMD) is the cheapest at 24. 9x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, Hologic, Inc. is actually cheaper at 17. 2x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — VMD or ISRG or HOLX or NVCR?

Over the past 5 years, Intuitive Surgical, Inc.

(ISRG) delivered a total return of +58. 7%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus NVCR's +30. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — VMD or ISRG or HOLX or NVCR?

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 41β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 437% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

05

Which is growing faster — VMD or ISRG or HOLX or NVCR?

By revenue growth (latest reported year), Viemed Healthcare, Inc.

(VMD) is pulling ahead at 20. 5% versus 1. 7% for Hologic, Inc. (HOLX). On earnings-per-share growth, the picture is similar: Viemed Healthcare, Inc. grew EPS 32. 1% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, VMD leads at 24. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — VMD or ISRG or HOLX or NVCR?

Intuitive Surgical, Inc.

(ISRG) is the more profitable company, earning 28. 4% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is VMD or ISRG or HOLX or NVCR more undervalued right now?

On forward earnings alone, Hologic, Inc.

(HOLX) trades at 17. 2x forward P/E versus 43. 8x for Intuitive Surgical, Inc. — 26. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

08

Which pays a better dividend — VMD or ISRG or HOLX or NVCR?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is VMD or ISRG or HOLX or NVCR better for a retirement portfolio?

For long-horizon retirement investors, Hologic, Inc.

(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41), +124. 3% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HOLX: +124. 3%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between VMD and ISRG and HOLX and NVCR?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VMD is a small-cap high-growth stock; ISRG is a mid-cap high-growth stock; HOLX is a mid-cap quality compounder stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

VMD

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 13%
  • Net Margin > 5%
Run This Screen
Stocks Like

ISRG

High-Growth Quality Leader

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 11%
  • Net Margin > 16%
Run This Screen
Stocks Like

HOLX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 7%
Run This Screen
Stocks Like

NVCR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 45%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform VMD and ISRG and HOLX and NVCR on the metrics below

Revenue Growth>
%
(VMD: 27.5% · ISRG: 23.0%)
Net Margin>
%
(VMD: 5.2% · ISRG: 28.2%)
P/E Ratio<
x
(VMD: 24.9x · ISRG: 57.6x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.